Effluent Biofluid Cell Assays for Therapy Response Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional therapeutics selection lacks a sufficiently informative sample for determining therapeutic efficacy, leading to unsatisfactory response and survival rates in cancer treatment, with immunotherapy often being a second-line therapy after traditional methods fail.
Innovation Solution
Analyzing biofluids, such as drain fluid and lymphatic effluent, for biomarkers like proteins, nucleic acids, and epigenetic markers to assess therapeutic efficacy and inform first-line therapeutic choices, using these fluids as part of the cell culture microenvironment to mimic the in vivo conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional blood-based biomarkers are used for therapeutic selection, then the diagnostic process is simple and non-invasive, but the information obtained is insufficient for accurate therapeutic efficacy determination
Solution Approach 1:
The patent uses effluent as an intermediary fluid that carries tumor-derived biomarkers from the tumor site to a collection point. This effluent serves as a mediator between the tumor tissue and the diagnostic analysis system, providing rich diagnostic information without requiring direct tissue biopsy.
Solution Approach 2:
The patent creates a surrogate sample (effluent) that copies the diagnostic information present in tumor tissue. By analyzing biomarkers in the effluent, which contains shed tumor cells and molecular debris, the system obtains tumor-specific diagnostic data without performing invasive tissue sampling.
2Measurement precision
If invasive tissue biopsies are performed to obtain sufficient diagnostic information, then therapeutic selection accuracy improves, but patient trauma and procedural complexity increase
Solution Approach 1:
The effluent acts as an intermediary that transports tumor-derived biomarkers to a diagnostic system, eliminating the need for direct tissue biopsy. This mediator approach provides sufficient diagnostic information while avoiding the harmful effects of invasive procedures.
Solution Approach 2:
The effluent serves as a surrogate copy of tumor tissue, containing sufficient biomarker information for accurate therapeutic selection. By analyzing this non-invasive copy, the system achieves high measurement precision without patient trauma.
3Loss of information
If effluent is analyzed for biomarkers to determine therapeutic efficacy, then diagnostic information quality improves, but the complexity of fluid collection and analysis increases
Solution Approach 1:
The effluent collection system is designed to serve multiple functions: it collects fluid from the surgical site, captures tumor-derived biomarkers, and provides a sample for diagnostic analysis. This multi-functional approach consolidates several processes into a single system, reducing overall complexity.
Solution Approach 2:
The effluent serves as a universal surrogate sample that can be used for multiple diagnostic purposes, including therapeutic selection and efficacy monitoring. By creating this versatile copy of tumor information, the system avoids the need for multiple separate sampling procedures.
4Reliability
If traditional chemotherapy and radiation are used as first-line therapy, then treatment protocols are well-established, but response rates are unsatisfactory and immunotherapy becomes a second-line option only
Solution Approach 1:
The patent performs preliminary diagnostic analysis of effluent biomarkers before initiating therapy to identify patients who will respond to immunotherapy. This preliminary action enables appropriate first-line therapy selection, improving response rates while maintaining protocol reliability through biomarker-guided decision-making.
Solution Approach 2:
The system uses effluent biomarker analysis to provide feedback on tumor characteristics and predicted therapy response. This feedback loop enables clinicians to select the most appropriate first-line therapy based on individual patient biomarker profiles, improving overall therapeutic response rates while maintaining treatment reliability.
Data Source
AI summary
The present invention provides methods for using waste effluent biofluids in cell culture assays as all or part of the cell culture microenvironment. Methods of the invention contemplate that biofluids typically regarded as waste may be used in cell-based assays to achieve a cell culture microenvironment that provides a novel understanding of cellular response.